Biotech Takes It on the Chin in May
PR Newswire (press release) - New York,NY,USA
... Index (-9.6%) Biogen Idec and Fumapharm AG announced positive
results from a Phase II study designed to evaluate the efficacy and
safety of BG-12, an oral ...
Biogen Idec Says BG-12 Meets Target In Phase II Study Of Relapsing ...
Trading Markets - Los Angeles,CA,USA
... Biogen Idec (BIIB | charts | news | PowerRating) said results from a
Phase II study designed to evaluate the efficacy and safety of BG-12
achieved its primary ...
Biogen drug does well in human trial
Triangle Business Journal - Raleigh,NC,USA
Biotech giant Biogen Idec announced Tuesday that its multiple sclerosis
drug BG-12 met its primary goals in a recent phase II human trial. ...
Oral Compound BG-12 Achieves Primary Endpoint in Phase II Study of ...
Genetic Engineering News - Larchmont,NY,USA
Biogen Idec (NASDAQ: BIIB) and Fumapharm AG announced positive results
from a Phase II study designed to evaluate the efficacy and safety of
BG-12, an oral ...
Encouraging phase II for Biogen Idec's multiple sclerosis drug
Pharmaceutical Business Review - USA
A phase II study, designed to evaluate Biogen Idec's investigational
oral fumarate BG-12 in patients with relapsing-remitting multiple
sclerosis, has yielded ...
See all stories on this topic
Zoek in het archief
Netherlands Corporate News (persbericht) - Netherlands
( BW)(BIOGEN-IDEC/FUMAPHARM)(BIIB) Oral Compound BG-12 Achieves Primary
Endpoint in Phase II Study of Relapsing-Remitting Multiple Sclerosis;
Treatment with BG ...
[Non-text portions of this message have been removed]